共查询到18条相似文献,搜索用时 93 毫秒
1.
目的探讨沙美特罗丙酸氟替卡松治疗慢性阻塞性肺疾病(简称慢阻肺)患者的临床疗效及其对免疫功能的影响。方法将100例慢阻肺患者随机分为观察组和对照组各50例。对照组采用常规治疗,观察组在此基础上给予沙美特罗丙酸氟替卡松吸入治疗。观察两组治疗后21天的临床疗效及治疗前后免疫功能指标变化。结果治疗组的有效率为96.00%明显高于对照组的有效率84.00%,差异有明显的统计学意义(P0.05),并且治疗后观察组CD+3,CD+4和CD+4/CD+8水平明显高于对照组,而CD+8水平明显低于对照组水平,差异有显著的统计学意义(P0.01),而Ig G,Ig A,Ig M水平治疗后两组无明显的统计学差异(P0.05)。结论沙美特罗丙酸氟替卡松治疗慢阻肺疗效确切,可改善患者免疫功能,值的临床推广应用。 相似文献
2.
目的运用评判性思维,分析老年重度慢性阻塞性肺疾病(COPD)患者在吸入沙美特罗联合丙酸氟替卡松后其肺功能的变化情况。方法以评判性思维为指导,随机将我院2009年1月~2011年9月住院治疗的80例老年重度COPD患者分为沙美特罗组(对照组∕A组)和沙美特罗联合丙酸氟替卡松组(实验组∕B组),A、B均给予常规吸氧、抗感染、化痰、平喘等常规条件下的对症治疗。A、B组入院治疗、出院后继续使用各自治疗方案并随访观察24周。A、B组均于治疗前及出院24周检查肺功能及血气分析等。结果治疗前A、B组的第1s用力呼气容积(FEV1)、用力肺活量(FVC)、FEV1/FVC、FEV1占预计值百分比(FEV1%)、PaO2、PaCO2等的差异均无统计意义(P〉0.05);治疗后B组较A组症状有明显改善(P〈0.05)。结论在分析评价的基础上,发现B组疗法对老年人重度COPD患者肺功能有显著作用,可以更好地促进患者康复。 相似文献
3.
目的探讨吸入型沙美特罗/丙酸氟替卡松(50/500)对非吸烟、稳定期COPD的治疗效果。方法因AECOPD住院后经治疗缓解的出院患者133例,随机分成3组,吸烟组52例,非吸烟组36例,吸入沙美特罗/丙酸氟替卡松(50/500)治疗,对照组45例,不吸入上述药物;3组患者随访12月,记录治疗前后SGRQ、肺功能、急性加重次数等。结果吸烟组治疗前后比较,肺功能、SGRQ明显改善,急性加重次数明显减少(P<0.05);而在非吸烟组和对照组上述指标治疗前后无显著差别(P>0.05)。结论沙美特罗/丙酸氟替卡松(50/500)可以改善吸烟组COPD患者生存状态、改善肺功能和减少急性加重,而非吸烟、稳定期COPD患者并没有从沙美特罗/丙酸氟替卡松(50/500)治疗中获益。 相似文献
4.
目的 观察沙美特罗/丙酸氟替卡松(舒利迭)联合噻托溴铵粉吸入剂(思力华)对慢性阻塞性肺疾病(COPD)缓解期的治疗效果.方法 采用随机、双肓的方法将85例COPD患者分为观察组和对照组,观察组A组给予噻托溴铵和沙美特罗/丙酸氟替卡松治疗,对照组B组给予沙美特罗/内酸氟替卡松治疗.分别对两组患者治疗前后的呼吸困难的评分、... 相似文献
5.
《中国老年学杂志》2016,(23)
目的系统评价沙美特罗/替卡松(丙酸氟替卡松)联用噻托溴铵治疗中、重度慢性阻塞性肺病(COPD)的临床疗效和安全性。方法计算机检索Pub Med、Ovid、CNKI、VIP、CBM、万方等数据库内有关沙美特罗/替卡松(丙酸氟替卡松)联用噻托溴铵,简称联合用药,与单用沙美特罗/替卡松(丙酸氟替卡松)或单用噻托溴铵治疗中、重度COPD的随机对照研究,检索年限为2000年1月至2014年7月,对纳入研究进行文献质量评价,采用Rev Man 5.2统计软件对结果进行分析。结果共纳入35篇文献,其中33篇为中文,2篇为英文,合计2 847例患者。Meta分析显示,联合用药对中、重度COPD患者肺功能、临床症状和生活质量的改善均优于单用沙美特罗/替卡松(沙美特罗/丙酸氟替卡松),除尚不能确定联合用药在降低动脉血二氧化碳分压(Pa CO2)优于单用噻托溴铵外,在肺功能、动脉血氧分压(Pa O2)和生活质量的改善也优于单用噻托溴铵。联合用药并没有增加不良反应的发生率,也没有加重不良反应的损害程度。结论沙美特罗/替卡松(丙酸氟替卡松)联用噻托溴铵治疗中、重度COPD是安全有效的。 相似文献
6.
目的 观察沙美特罗替卡松干粉吸入剂对慢性阻塞性肺疾病(COPD)的疗效及安全性.方法 将76饲COPD患者随机分为两组.对照组38例口服氨茶碱,3次/d,0.1g/次;治疗组38例吸入沙美特罗替卡松干粉剂,2次/d,1吸/次,疗程为半年.观察两组患者治疗前后肺功能变化.结果 治疗后,治疗组肺功能指标明显优于对照组.结论 沙美特罗替卡松干粉吸入能够改善慢性阻塞性肺疾病的肺功能. 相似文献
7.
目的比较长期联合吸入布地奈德/福莫特罗和沙美特罗/氟替卡松对中重度稳定期COPD病人的肺功能、生活质量的影响。方法 60例中重度稳定期COPD病人随机分为规律吸入布地奈德/福莫特罗(160μg/4.5μg)20例,规律吸入沙美特罗/氟替卡松(50μg/250μg)20例,按需吸入特布他林组20例(对照组)。测定三组试验前及试验后6个月圣·乔治(St·George)呼吸疾病问卷(SGRQ)的评分、6分钟行走距离(6-MWD)、肺功能。结果布地奈德/福莫特罗组与沙美特罗/氟替卡松组治疗后较对照组生活质量改善、6-MWD增加、肺功能改善,差异有统计学意义(P〈0.05);布地奈德/福莫特罗组与沙美特罗/氟替卡松组间比较,差异无统计学意义(P〉0.05)。结论与沙美特罗/氟替卡松一样,规律吸入布地奈德/福莫特罗能改善中重度稳定期COPD病人的临床症状、运动耐力和肺功能。 相似文献
8.
目的为进一步规范慢性阻塞性肺疾病患者正确使用沙美特罗/氟替卡松吸入剂。方法采用问卷调查法,对106例慢阻肺患者进行沙美特罗/氟替卡松吸入剂使用情况的调查。结果操作基本正确的68例,正确率为64.15%;操作不正确的38例,错误率为35.85%。常见的错误有使用前未摇匀准纳器(46.23%)、吸药时未用力按下准纳器顶部(29.25%)、吸药前未深呼气(24.53%)、吸药后未屏气或屏气不10秒(22.64%)、吸药时未及时或不正确漱口(20.75%)、吸药时未深吸(19.81%)、口含准纳器时有漏气(10.38%)等。年龄较小及文化程度越高的正确率较高,在医药护指导下使用正确率较高,年龄较大及文化程度较低的患者使用正确率较低。结论沙美特罗/氟替卡松吸入剂在慢阻肺患者中正确使用情况不容乐观,应采取相应措施提高其使用正确率。 相似文献
9.
目的:探讨沙美特罗氟替卡松联合噻托溴铵对重度慢性阻塞性肺疾病(COPD)稳定期患者的疗效。方法将45例重度 COPD 稳定期的患者随机均分为3组,第1组吸入沙美特罗氟替卡松的治疗;第2组吸入噻托溴铵的治疗;第3组吸入沙美特罗氟替卡松联合噻托溴铵。疗程为6个月,比较治疗前后英国医学委员会呼吸困难问卷分级(mMRC 问卷)、6分钟步行试验(6MWT)、肺功能改善情况和血气分析指标。结果第3组患者的第1秒用力呼气容积(FEV1)、FEV1/用力肺活量(FVC)均显著提高(P <0.05),第3组患者治疗后的 FEV1改善率为(19.11±3.52)%;PaO2显著提高(P <0.05),第3组患者治疗后的 PaO2改善率为(22.35±5.18)%,显著减缓肺功能的恶化情况。另外联合治疗组 mMRC 问卷、6分钟步行距离(6MWD)明显改善(P <0.05),患者运动耐量改善。结论吸入沙美特罗氟替卡松联合噻托溴铵要比单纯使用沙美特罗氟替卡松或噻托溴铵具有更好的疗效。 相似文献
10.
11.
Lyseng-Williamson KA Keating GM 《American journal of respiratory medicine : drugs, devices, and other interventions》2002,1(4):273-82; discussion 283-4
Salmeterol/fluticasone propionate is a fixed-dose combination of the long-acting beta2-adrenoceptor agonist salmeterol and the corticosteroid fluticasone propionate and is inhaled via the Diskus powder inhaler. In three randomized, double-blind, 24-week or 52-week studies in >2850 patients with chronic obstructive pulmonary disease (COPD), administration of salmeterol/fluticasone propionate 50/250 microg twice daily (in one study) and salmeterol/fluticasone propionate 50/500 microg twice daily (in the other studies) provided greater improvement in lung function than placebo or either component alone at the same nominal dosage. Both strengths of the combination product administered twice daily resulted in clinically meaningful increases in scores in health-related quality-of-life questionnaires that were specific for respiratory disease. Improvements in this and almost all other secondary measures of efficacy, including symptomatic outcomes, were significantly greater with the combination product than with placebo. Administration of salmeterol/fluticasone propionate as a combination product did not result in any untoward interactions that affected the pharmacodynamic, pharmacokinetic or tolerability profiles of the individual components. Candidiasis, hoarseness/dysphonia, throat irritation and headache occurred more frequently with salmeterol/fluticasone propionate than with placebo in patients with COPD. 相似文献
12.
Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease 总被引:3,自引:0,他引:3
Kardos P Wencker M Glaab T Vogelmeier C 《American journal of respiratory and critical care medicine》2007,175(2):144-149
RATIONALE: Exacerbations of chronic obstructive pulmonary disease (COPD) greatly contribute to declining health status and the progression of the disease, thereby incurring significant direct and indirect health care costs. The prevention of exacerbations, therefore, is an important treatment goal. OBJECTIVES: To assess the impact of combination therapy with salmeterol/fluticasone propionate compared with salmeterol alone on moderate and severe exacerbations in patients with severe COPD and a history of repeated exacerbations. METHODS: Randomized, double-blind, parallel-group study. After a 4-wk run-in period, 994 clinically stable patients were randomized to one of two treatment groups: 507 patients received the salmeterol/fluticasone combination 50/500 micro g twice daily and 487 received salmeterol 50 micro g twice daily for 44 wk. MAIN RESULTS: The total number of exacerbations was 334 in the combination therapy and 464 in the salmeterol group (p < 0.0001). The annualized rate of moderate and severe exacerbations per patient was 0.92 in the combination therapy and 1.4 in the salmeterol group, corresponding to a 35% decrease. In addition, the mean time to first exacerbation in the combination therapy group was significantly longer compared with that of the salmeterol group (128 vs. 93 d, p < 0.0001). Other endpoints, including health-related quality of life, peak expiratory flow, and use of rescue medication, were significantly improved in the combination therapy group. Both treatments were well tolerated. CONCLUSIONS: This study demonstrates that combination therapy with salmeterol/fluticasone compared with salmeterol monotherapy significantly reduces the frequency of moderate/severe exacerbations in patients with severe COPD. 相似文献
13.
目的 探讨噻托溴铵(思力华)联合沙美特罗替卡松(舒利迭)吸入治疗中重度支气管哮喘(简称哮喘)合并慢性阻塞性肺疾病(COPD)的临床疗效.方法 将126例中重度哮喘合并COPD患者随机分人对照组与观察组,对照组患者接受沙美特罗替卡松吸入,给予观察组患者噻托溴铵联合沙美特罗替卡松吸入.比较两组患者治疗前及治疗后1年肺功能的改变,急性发作次数、住院次数、急性发作的间隔时间以及生活质量.结果 治疗后观察组第1秒用力呼气容积(FEV1)、FEV1占预计值百分比(FEVt%pred)和用力肺活量(FVC)显著优于对照组(P<0.05);随访1年,观察组急性发作次数及住院次数显著少于对照组(P<0.05),急性发作的间隔时间差异无统计学意义(P>0.05);观察组生活质量SGRQ评分各维度及总分显著低于对照组,差异有统计学意义(P<0.05).结论 噻托溴铵联合沙美特罗替卡松吸入可显著改善中重度哮喘合并CO PD患者肺功能,提高临床疗效及患者生活质量. 相似文献
14.
目的 探讨噻托溴铵(思力华)与沙美特罗替卡松(舒利迭)联合吸入治疗COPD稳定期临床效果.方法 选取2013年7月至2015年2月于我院诊治的COPD稳定期患者共102例进行研究,随机原则分为研究组(n=53例)和对照组(n=49例),对照组实施沙美特罗替卡松治疗、研究组在沙美特罗替卡松治疗基础上加用噻托溴铵治疗.比较2组患者治疗前后血气指标、肺功能、呼吸困难评分、生活质量评分;并评定临床疗效、并发症情况.结果 2组患者治疗后的PaCO2指标、呼吸困难分级(medicine research council scale,mMRC)评分、COPD评估测试(COPD assessment test,CAT)评分均较治疗前降低(t研究组=4.745、2.724、5.211,t对照组=3.224、2.317、3.617,P<0.05),且研究组较对照组降低更明显(t=3.514、5.263、4.263,P<0.05);2组患者治疗后的PaO2指标、FEV1/FVC指标、FEV1指标均较治疗前升高(t研究组=5.212、2.738、5.926,t对照组=4.413、2.382、5.014,P<0.05),且研究组较对照组升高更明显(t=4.514、2.505、4.815,P<0.05);研究组与对照组总有效率分别为88.68%和71.42%,研究组高于对照组(x2=4.814,P<0.05);2组并发症发生情况差异无统计学意义(x2=0.625,P>0.05).结论 对临床中COPD稳定期患者实施噻托溴铵与沙美特罗替卡松联合吸入治疗,血气指标、肺功能、生活质量明显改善,效果显著,值得推广. 相似文献
15.
Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease 总被引:3,自引:0,他引:3
Barnes NC Qiu YS Pavord ID Parker D Davis PA Zhu J Johnson M Thomson NC Jeffery PK;SCO Study Group 《American journal of respiratory and critical care medicine》2006,173(7):736-743
RATIONALE: No currently available treatment is reported to reduce the exaggerated airway wall inflammation of chronic obstructive pulmonary disease. OBJECTIVES: We tested the hypothesis that inhaled combined long-acting beta2-agonist (salmeterol) and corticosteroid (fluticasone propionate) will reduce inflammation. METHODS: Bronchial biopsies and induced sputum were taken from 140 current and former smokers (mean age, 64 yr) with moderate to severe disease, randomized in a 13-wk double-blind study to placebo (n = 73) or salmeterol/fluticasone propionate 50/500 microg (n = 67) twice daily. Biopsies were repeated at 12 wk and sputa at 8 and 13 wk. After adjustment for multiplicity, comparisons between active and placebo were made for median change from baseline in the numbers of biopsy CD8+ and CD68+ cells/mm2 and sputum neutrophils. MEASUREMENTS AND MAIN RESULTS: Combination therapy was associated with a reduction in biopsy CD8+ cells of -118 cells/mm2 (95% confidence interval [CI], -209 to -42; p = 0.02), a reduction of 36% over placebo (p = 0.001). CD68+ cells were unaffected by combination treatment. Sputum differential (but not total) neutrophils reduced progressively and, at Week 13, significantly with combination treatment (median treatment difference, 8.5%; 95% CI, 1.75%-15.25%; p = 0.04). The combination also significantly reduced biopsy CD45+ and CD4+ cells and cells expressing genes for tumor necrosis factor-alpha and IFN-gamma and sputum total eosinophils (all p < or = 0.03). These antiinflammatory effects were accompanied by a 173-ml (95% CI, 104-242; p < 0.001) improvement in prebronchodilator FEV1. CONCLUSIONS: The combination of salmeterol and fluticasone propionate has a broad spectrum of antiinflammatory effects in both current and former smokers with chronic obstructive pulmonary disease, which may contribute to clinical efficacy. 相似文献
16.
目的探讨噻托溴铵联合沙美特罗/丙酸氟替卡松联合治疗稳定期慢性阻塞性肺疾病(COPD)的临床效果。方法采用随机的方法将93例稳定期COPD患者分为观察组(47例)和对照组(46例),两组均予常规基础治疗,观察组给予沙美特罗/丙酸氟替卡松(50μg/500μg,2次/d)联合噻托溴铵(18μg,1次/d)吸入治疗,对照组给予沙美特罗/丙酸氟替卡松(50μg/500μg,2次/d)单独吸入治疗,疗程为9个月。观察患者治疗前与治疗后12、24、36周运动耐量、呼吸困难评分以及肺功能的变化。结果治疗后两组患者6min步行距离(6MWD)值、肺功能均有显著增加(P0.05),呼吸困难评分(MRC)均有显著下降(P0.05),而观察组各项指标改善明显优于对照组(P0.05)。结论沙美特罗/丙酸氟替卡松单用可有效缓解稳定期COPD患者的临床症状、改善肺功能。而沙美特罗/丙酸氟替卡松联合噻托溴铵在减轻患者临床症状,改善肺功能上的作用更为显著,值得临床推广应用。 相似文献
17.
Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease 总被引:17,自引:0,他引:17
Mahler DA Wire P Horstman D Chang CN Yates J Fischer T Shah T 《American journal of respiratory and critical care medicine》2002,166(8):1084-1091
This randomized controlled trial examined the benefits of combining an inhaled corticosteroid, fluticasone propionate (F), with an inhaled long-acting beta(2)-agonist, salmeterol (S), to treat the inflammatory and bronchoconstrictive components of chronic obstructive pulmonary disease (COPD). A total of 691 patients with COPD received the combination of F and S (FSC), S (50 mcg), F (500 mcg), or placebo twice daily via the Diskus device for 24 weeks. A significantly greater increase in predose FEV(1) at the endpoint was observed after FSC (156 ml) compared with S (107 ml, p = 0.012) and placebo (-4 ml, p < 0.0001). A significantly greater increase in 2-hour postdose FEV(1) at the endpoint was observed after treatment with FSC (261 ml) compared with F (138 ml, p < 0.001) and placebo (28 ml, p < 0.001). There were greater improvements in the Transition Dyspnea Index with FSC (2.1) compared with F (1.3, p = 0.033), S (0.9, p < 0.001), and placebo (0.4, p < 0.0001). The incidence of adverse effects (except for an increase in oral candidiasis with FSC and F) was similar among the treatment groups. We conclude that FSC improved lung function and reduced the severity of dyspnea compared with individual components and placebo. 相似文献